dr. kerrigan on remaining challenges in ros1 nsclc
Published 4 years ago • 59 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
1:25
dr. kerrigan on remaining challenges in alk nsclc
-
0:59
dr. kerrigan on design and findings of the profile 1001 trial in ros1-mutated nsclc
-
1:41
dr. pennell on remaining challenges in nsclc
-
2:12
dr. drilon on entrectinib in patients with ros1-positive nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
1:45
dr. feliciano on ros1-targeted therapy in nsclc
-
1:51
dr. riess on ros1 fusions in lung cancer
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
1:14
dr. murphy on glioma prognostic factors in younger patients
-
0:07
reasons why you will not be a doctor #shorts
-
0:57
dr. pant on choosing therapy for frontline and beyond in pancreatic cancer
-
1:45
dr. herbst discusses challenges with immunotherapy in nsclc
-
1:53
ros-1 rearrangements: what are they?
-
1:22
dr. mason on the intersection of surgery and biomarkers in nsclc
-
0:57
dr. decker discusses aes associated with radiation in lung cancer
-
3:31
the evolution of alk/ros1-targeted tkis
-
0:22
detect lung cancer early
-
4:43
upfront therapy for alk/ros1-rearranged nsclc
-
1:10
dr. gubens on prevalence of egfr/alk/ros1 and pd-l1 expression in nsclc